The AHA Guidelines and Scientifi c Statements Handbook
f. Mechanical support of the failing heart
Intra-aortic balloon counterpulsation
Class I
1 Intra-aortic balloon counterpulsation should be
used in STEMI patients with hypotension (systolic
blood pressure less than 90 mm Hg or 30 mm Hg
below baseline mean arterial pressure) who do not
respond to other interventions, unless further support
is futile because of the patient’s wishes or contraindica-
tions/unsuitability for further invasive care. See Section
7.6.2 of the full-text guidelines. (Level of Evidence: B)
2 Intra-aortic balloon counterpulsation is recom-
mended for STEMI patients with low-output state.
See Section 7.6.3 of the full-text guidelines. (Level of
Evidence: B)
3 Intra-aortic balloon counterpulsation is recom-
mended for STEMI patients when cardiogenic shock
is not quickly reversed with pharmacological
therapy. IABP is a stabilizing measure for angiogra-
phy and prompt revascularization. See Section 7.6.5
of the full-text guidelines. (Level of Evidence: B)
4 Intra-aortic balloon counterpulsation should be
used in addition to medical therapy for STEMI
patients with recurrent ischemic-type chest discom-
fort and signs of hemodynamic instability, poor LV
function, or a large area of myocardium at risk. Such
patients should be referred urgently for cardiac cath-
eterization and should undergo revascularization as
needed. See Section 7.8.2 of the full-text guidelines.
(Level of Evidence: C)
Class IIa
It is reasonable to manage STEMI patients with
refractory polymorphic VT with intra-aortic balloon
counterpulsation to reduce myocardial ischemia.
See Section 7.7.1.2 of the full-text guidelines. (Level
of Evidence: B)
Class IIb
It may be reasonable to use intra-aortic balloon coun-
terpulsation in the management of STEMI patients
with refractory pulmonary congestion. See Section
7.6.4 of the full-text guidelines. (Level of Evidence: C)
F. Arrhythmias after STEMI
- Ventricular arrhythmias
a. Ventricular fi brillation
Class I
Ventricular fi brillation (VF) or pulseless VT should
be treated with an unsynchronized electric shock
with an initial monophasic shock energy of 200 J; if
unsuccessful, a second shock of 200 to 300 J should
be given, and then, if necessary, a third shock of
360 J. (Level of Evidence: B)Class IIa
1 It is reasonable that VF or pulseless VT that is
refractory to electrical shock be treated with amio-
darone (300 mg or 5 mg/kg, IV bolus) followed by
a repeat unsynchronized electric shock. (Level of Evi-
dence: B)
2 It is reasonable to correct electrolyte and acid-
base disturbances (potassium greater than 4.0 mEq/
L and magnesium greater than 2.0 mg/dL) to prevent
recurrent episodes of VF once an initial episode of
VF has been treated. (Level of Evidence: C)Class IIb
It may be reasonable to treat VT or shock-refractory
VF with boluses of intravenous procainamide.
However, this has limited value owing to the length
of time required for administration. (Level of
Evidence: C)Class III
Prophylactic administration of antiarrhythmic
therapy is not recommended when using fi brinolytic
agents. (Level of Evidence: B)b. Ventricular tachycardia
Class I
1 Sustained (more than 30 seconds or causing
hemodynamic collapse) polymorphic VT should be
treated with an unsynchronized electric shock with
an initial monophasic shock energy of 200 J; if
unsuccessful, a second shock of 200 to 300 J should
be given, and, if necessary, a third shock of 360 J.
(Level of Evidence: B)
2 Episodes of sustained monomorphic VT associ-
ated with angina, pulmonary edema, or hypotension
(blood pressure less than 90 mm Hg) should be
treated with a synchronized electric shock of 100 J
initial monophasic shock energy. Increasing ener-
gies may be used if not initially successful. Brief
anesthesia is desirable if hemodynamically tolerable.
(Level of Evidence: B)
3 Sustained monomorphic VT not associated with
angina, pulmonary edema, or hypotension (blood
pressure less than 90 mm Hg) should be treated with: